Nashville、TNにおける結腸癌の臨床試験
Nashvilleとその周辺地域（約30マイル以内）の拠点で、結腸癌に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of PHN-012 in Patients With Advanced Solid Tumors
被験者募集中第1相
- PHN-012-001 Site, Nashville
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
被験者募集中第3相
- Henry-Joyce Cancer Clinic, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institue, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
被験者募集中第1/2相
- Tennessee Oncology, PLLC, Nashville
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
被験者募集中第1/2相
- GSK Investigational Site, Nashville
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
被験者募集中第2/3相
- Vanderbilt University/Ingram Cancer Center, Nashville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
被験者募集中第1相
- Xencor Investigative Site, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
被験者募集中第1相
- Sarah Cannon, SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- Vanderbilt University Medical Center, Nashville
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
被験者募集中第2相
- SCRI Oncology Partners, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
被験者募集中観察研究
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Nashville
他の都市における結腸癌の試験
- Boston, MA22件の研究
- New York City, NY22件の研究
- Houston, TX20件の研究
- Los Angeles, CA16件の研究
- St. Louis, MO15件の研究
- Arlington, VA15件の研究
- Chicago, IL14件の研究
- San Antonio, TX14件の研究
- Baldwin Park, CA14件の研究
- Baltimore, MD13件の研究
- Tampa, FL13件の研究
- Washington, DC12件の研究
Nashvilleにおける他の研究
- 非小細胞肺癌97件の研究
- 乳がん81件の研究
- 転移性癌70件の研究
- 大腸癌69件の研究
- がん（全種類）65件の研究
- 卵巣がん49件の研究
- 前立腺がん43件の研究
- 肺がん40件の研究
- 頭頸部扁平上皮癌39件の研究
- 膵臓がん39件の研究
- 子宮内膜がん38件の研究
- 悪性黒色腫33件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。